Comparative Pharmacology
Head-to-head clinical analysis: CORTAN versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTAN versus TOPICORT.
CORTAN vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
5-60 mg orally once daily, titrated to the lowest effective dose. Maintenance: 5-20 mg daily.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Terminal elimination half-life 1.5–2 hours; clinical context: short duration requires multiple daily doses for sustained effect
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal: 80% as metabolites and unchanged drug; biliary/fecal: 20%
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid